Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients (scientific article published in January 2004)

Ability of a first-pass pharmacokinetic model to characterize cyclosporine blood concentrations after administrations of Sandimmune or Neoral formulations.

Q52244872

A population pharmacokinetic model of cyclosporine in the early postoperative phase in patients with liver transplants, and its predictive performance with Bayesian fitting.

Q52244875

Some suggestions for measuring predictive performance

Q52875851

Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay.

Q52907110

Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy

Q73078589

Evaluation of limited sampling strategies for estimation of 12-hour mycophenolic acid area under the plasma concentration-time curve in adult renal transplant patients

Q73084381

Mycophenolic acid concentrations are associated with cardiac allograft rejection

Q73187179

Enterohepatic circulation model for population pharmacokinetic analysis

Q73223145

Relationship between mycophenolate mofetil side effects and mycophenolic acid plasma trough levels in renal transplant patients

Q73266858

Evaluation of an immunoassay for mycophenolic acid

Q73477996

Limited sampling strategy for mycophenolic acid area under the curve

Q73696977

Mycophenolic acid area under the curve values in African American and Caucasian renal transplant patients are comparable

Q73927459

Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients

Q74685641

Relation of mycophenolic acid trough levels and adverse events in kidney allograft recipients

Q74685660

The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation

Q77743596

Trough blood concentrations in long-term treatment with mycophenolate mofetil

Q77747400

Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels

Q77871423

Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPA-AUC in paediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy

Q78174381

A retrospective analysis of mycophenolic acid and cyclosporin concentrations with acute rejection in renal transplant recipients

Q32139934

Software for population pharmacokinetics and pharmacodynamics

Q33631602

Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Reci

Q33845624

Pharmacokinetics of mycophenolic acid in renal insufficiency

Q33845628

Methods for clinical monitoring of cyclosporin in transplant patients.

Q33937533

Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion

Q34321841

Therapeutic drug monitoring for immunosuppressants

Q34428221

Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary?

Q34660691

Computers in pharmacokinetics. Choosing software for clinical decision making

Q40772751

Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting.

Q40953450

Mycophenolic acid: measurement and relationship to pharmacologic effects.

Q40962218

Predictive performance of the Bayesian analysis: effects of blood sampling time, population parameters, and pharmacostatistical model

Q41045157

The use of population pharmacokinetics in drug development

Q41201505

The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.

Q42670520

Determination of mycophenolate area under the curve by limited sampling strategy.

Q43552861

Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.

Q43654390

Application of a gamma model of absorption to oral cyclosporin

Q43658099

Therapeutic drug level monitoring for mycophenolate mofetil: is it justified?

Q43702799

Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients

Q43817892

Maximum a posteriori Bayesian estimation of oral cyclosporin pharmacokinetics in patients with stable renal transplants

Q43875084

Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy.

Q43893212

Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategy.

Q43898724

Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection

Q43993075

Monitoring mycophenolic acid

Q44011249

Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee--Japan.

Q44048560

Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus

Q44113701

Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication

Q44157281

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection

Q46246052

Clinical pharmacokinetics of mycophenolate mofetil

Q46787320

A program for the optimization of cyclosporine therapy using population kinetics modeling.

Q52082260

Evaluation of the EMIT Mycophenolic Acid Assay from Dade Behring.

Q52132337

A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation.

Q52207472

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

pharmacokinetics

Q323936

P304

page(s)

253-266

P577

publication date

2004-01-01

P1433

published in

Clinical Pharmacokinetics

Q5133788

P1476

title

Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients

P478

volume

Reverse relations

cites work (P2860)

Q46608340	A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil
Q35843096	A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients
Q43921775	Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients
Q35826755	Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.
Q38242804	Clinical mycophenolic acid monitoring in liver transplant recipients
Q38087925	Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease
Q34573738	Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients
Q46506762	Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients.
Q36111207	Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.
Q38223136	Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?
Q91710479	Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients
Q37135382	High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
Q38170321	How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?
Q35980234	Immunosuppressant drug monitoring: is the laboratory meeting clinical expectations?
Q37591508	Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions
Q47322868	Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients
Q36407345	Individualization of mycophenolate mofetil dose in renal transplant recipients.
Q37737279	Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study
Q35619332	Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients
Q88594354	Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients
Q43264540	Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus
Q37581617	Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review.
Q42597049	Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients.
Q37956717	Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?
Q46040442	Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.
Q51768893	Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study.
Q46076329	Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study
Q37824525	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure.
Q90494250	Pharmacokinetic evaluation of MFF in combinations with tacrolimus and cyclosporine. Findings of C0 and AUC
Q34610933	Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I
Q37586449	Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part II.
Q46706107	Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies
Q58785681	Pharmacokinetics of Mycophenolate Mofetil and Development of Limited Sampling Strategy in Early Kidney Transplant Recipients
Q51916162	Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients.
Q34152549	Population Pharmacokinetics of Mycophenolic Acid and Metabolites in Patients With Glomerulonephritis
Q34570937	Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period
Q38610665	Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients
Q33764995	Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.
Q36728151	Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil
Q28272907	Population pharmacokinetics and pharmacogenetics of mycophenolic acid following administration of mycophenolate mofetil in de novo pediatric renal-transplant patients
Q46233584	Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients
Q36336060	Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.
Q46622999	Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation
Q34180482	Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation
Q46714356	Population pharmacokinetics of mycophenolic acid in renal transplant recipients.
Q37818144	The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease
Q56380780	The utility of trough mycophenolic acid levels for the management of lupus nephritis
Q36788423	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?
Q36024478	Time-dependent clearance of mycophenolic acid in renal transplant recipients
Q43224167	Validation of limited sampling strategy for estimation of mycophenolic acid exposure during the first year after heart transplantation.

P6179	Dimensions Publication ID	1033093527
P356	DOI	10.2165/00003088-200443040-00004
P698	PubMed publication ID	15005639